NeOnc Technologies Schedules FDA In-Person End-of-Phase 1 Type B Meeting Concerning NEO212 For November 17
The Company plans to seek FDA feedback on its NEO212 clinical development program, including an update to its proposed patient population, trial design, endpoints, dose selection and evidence needed to support a future
NeOnc is meeting with FDA regulators to get feedback on their new medicine NEO212. This meeting helps them plan the next steps before testing the drug on more patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.